Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

POLYSTYRENE SODIUM SULFONATE

All products: not a benefit

Other products in the same Health Canada class (V03AE) — coverage varies; not interchangeable

  • Lanthanum (Fosrenol): not a benefit
  • Sevelamer carbonate (Renvela): not a benefit

Odan-Sodium Polystyrene Sulfonate · DIN 02473968 · 250mg/mL · oral liquid

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Odan-Sodium Polystyrene Sulfonate · DIN 02473968 Manufacturer: Odan Laboratories Ltd.; listing date 2019-07-31 Health Canada: Marketed since 2018-12-11 · brand ODAN-SODIUM POLYSTYRENE SULFONATE · ATC V03AE01 POLYSTYRENE SULPHONATE · form Suspension · route Oral, Rectal · ingredients SODIUM POLYSTYRENE SULFONATE 250 MG/ML · company Odan laboratoriesltd · schedule Prescription
Check this DIN again · Health Canada product record

Odan-Sodium Polystyrene Sulfonate: Formulary list price $0.1954/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1954 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96397 · Verify on the e-Formulary ↗ (DIN 02473968)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02473968). DIN 02473968: Odan-Sodium Polystyrene Sulfonate Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 401800004; group id 551; item number 1486; lccId None; manufacturer id ODN Source form: O/L; strength: 250mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.1954; ministry $0.1954 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473968 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96397
Interchangeable products
Solystat · DIN 00769541 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (40:18 Potassium-Removing Resins) and how they are covered

Matched class: 40:18 Potassium-Removing Resins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 40:18 Potassium-Removing Resins

LANTHANUM

· 8 products · Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 250mg, 500mg, 750mg, 1000mg · Chew Tab

SEVELAMER CARBONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 800mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:18
Full class listing Related classes: 40:12 Replacement Agents, 40:28 Diuretics, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATION SOLYSTAT (sodium polystyrene sulfonate suspension) is indicated for the treatment of hyperkalemia. https://pdf.hres.ca/dpd_pm/00078001.PDF PM date: December 5, 2024 Source product: SOLYSTAT; DIN 00755338; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Odan-Sodium Polystyrene Sulfonate: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026